Longeveron (LGVN) Other Non-Current Liabilities (2024 - 2025)
Longeveron (LGVN) posted quarterly Other Non-Current Liabilities of $330000.0 for Q4 2025, up 24.53% year-over-year from $265000.0 in Q4 2024, and up 4.76% quarter-over-quarter from $315000.0 in Q3 2025.
Longeveron (LGVN) Other Non-Current Liabilities (2024 - 2025) Analysis & Trends
Longeveron's Other Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $330000.0 for Q4 2025.
- In Q4 2025, Other Non-Current Liabilities rose 24.53% year-over-year to $330000.0; the TTM figure through Dec 2025 stood at $330000.0 (up 24.53% YoY), while the FY2025 annual figure was $330000.0, up 24.53% from the prior year.
- Other Non-Current Liabilities for Q4 2025 stood at $330000.0, up from $315000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $330000.0 in Q4 2025, with the low at $66000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 330,000.00 |
| Sep 30, 2025 | 315,000.00 |
| Jun 30, 2025 | 308,000.00 |
| Mar 31, 2025 | 302,000.00 |
| Dec 31, 2024 | 265,000.00 |
| Sep 30, 2024 | 199,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Mar 31, 2024 | 66,000.00 |